Antagonizing the calcium-sensing receptor: Towards new bone anabolics?

Current Molecular Pharmacology

Volumn 5, Issue 2, 2012, Pages 182-188

  Riccardi, Daniela ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Bisphosphonates; Calcilytics; Calcium sensing receptor (CaSR); Osteoblast; Osteoclast; Osteoporosis; Parathormone (PTH)

Indexed keywords

ALENDRONIC ACID; CALCIUM SENSING RECEPTOR; DENOSUMAB; IBANDRONIC ACID; JTT 305; ODANACATIB; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE MINERAL; CLINICAL TRIAL; HUMAN; LONG TERM CARE; NONHUMAN; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; VERTEBRA FRACTURE;

EID: 84861723492     PISSN: 18744672     EISSN: 18744702     Source Type: Journal    
DOI: 10.2174/1874467211205020182     Document Type: Review

References (64)

1. Siris, E.S.; Chen, Y.T.; Abbott, T.A.; Barrett-Connor, E.; Miller, P.D.; Wehren, L.E.; Berger, M.L. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch. Intern. Med., 2004, 164, 1108-1112.
2. Khosla, S.; Westendorf, J.J.; Oursler, M.J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest., 2008, 118, 421-428.
3. Gallacher, S.J.; Dixon, T. Impact of Treatments for Postmenopausal Osteoporosis (Bisphosphonates, Parathyroid Hormone, Strontium Ranelate, and Denosumab) on Bone Quality: A Systematic Review. Calcif. Tissue Int., 2010, 87(6), 469-484.
4. Riggs, B.L.; Wahner, H.W.; Melton, L.J. 3rd; Richelson, L.S.; Judd, H.L.; Offord, K.P. Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J. Clin. Invest., 1986, 77, 1487-1491.
5. Seeman, E. Advances in therapeutics: Meetiing report from the 31st Annual Meeting of the American Society for Bone and Mineral Research. IBMS BoneKEy, 2009, 6, 496-502.
6. Green, J.; Czanner, G.; Reeves, G.; Watson, J.; Wise, L.; Beral, V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ, 2010, 341, c4444.
7. Wagner, E.R.; Zhu, G.; Zhang, B.Q.; Luo, Q.; Shi, Q.; Huang, E.; Gao, Y.; Gao, J.L.; Kim, S.H.; Rastegar, F.; Yang, K.; He, B.C.; Chen, L.; Zuo, G.W.; Bi, Y.; Su, Y.; Luo, J.; Luo, X.; Huang, J.; Deng, Z. L.; Reid, R.R.; Luu, H.H.; Haydon, R.C.; He, T.C. The Therapeutic Potential of the Wnt Signaling Pathway in Bone Disorders. Curr. Mol. Pharmacol., 2011, 4(1), 14-25.
8. Krishnan, V.; Bryant, H.U.; Macdougald, O.A. Regulation of bone mass by Wnt signaling. J. Clin. Invest., 2006, 116, 1202-1209.
9. Canalis, E.; Giustina, A.; Bilezikian, J.P. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med., 2007, 357, 905-916.
10. Hock, J.M.; Gera, I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J. Bone Miner. Res., 1992, 7, 65-72.
11. Dobnig, H.; Turner, R.T. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology, 1997, 138, 4607-4612.
12. Ishizuya, T.; Yokose, S.; Hori, M.; Noda, T.; Suda, T.; Yoshiki, S.; Yamaguchi, A. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J. Clin. Invest., 1997, 99, 2961-2970.
13. Neer, R.M.; Arnaud, C.D.; Zanchetta, J.R.; Prince, R.; Gaich, G.A.; Reginster, J.Y.; Hodsman, A.B.; Eriksen, E.F.; Ish-Shalom, S.; Genant, H.K.; Wang, O.; Mitlak, B.H. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med., 2001, 344, 1434-1441.
14. Nemeth, E.F. The parathyroid polyhormone hypothesis revisited. Kidney Int. Suppl., 2006, (102), S22-28.
15. Tovey, S.C.; Dedos, S.G.; Taylor, C.W. Signalling from parathyroid hormone. Biochem. Soc. Trans., 2006, 34, 515-517.
16. Rixon, R.H.; Whitfield, J.F.; Gagnon, L.; Isaacs, R.J.; Maclean, S.; Chakravarthy, B.; Durkin, J.P.; Neugebauer, W.; Ross, V.; Sung, W. Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. J. Bone Miner. Res., 1994, 9, 1179-1189.
17. Jouishomme, H.; Whitfield, J. F.; Gagnon, L.; Maclean, S.; Isaacs, R.; Chakravarthy, B.; Durkin, J.; Neugebauer, W.; Willick, G.; Rixon, R. H. Further definition of the protein kinase C activation domain of the parathyroid hormone. J Bone Miner Res, 1994, 9, 943-949.
18. Kneissel, M.; Boyde, A.; Gasser, J.A. Bone tissue and its mineralization in aged estrogen-depleted rats after long-term intermittent treatment with parathyroid hormone (PTH) analog SDZ PTS 893 or human PTH(1-34). Bone, 2001, 28, 237-250.
19. Lane, N.E.; Sanchez, S.; Modin, G.W.; Genant, H.K.; Pierini, E.; Arnaud, C.D. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoidinduced osteoporosis: results of a randomized controlled clinical trial. J. Bone Miner. Res., 2000, 15, 944-951.
20. Lindsay, R.; Nieves, J.; Formica, C.; Henneman, E.; Woelfert, L.; Shen, V.; Dempster, D.; Cosman, F. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet, 1997, 350, 550-555.
21. Vahle, J.L.; Sato, M.; Long, G.G.; Young, J.K.; Francis, P.C.; Engelhardt, J.A.; Westmore, M.S.; Linda, Y.; Nold, J.B. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol. Pathol., 2002, 30, 312-321.
22. Tashjian, A. H. Jr.; Goltzman, D. On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J. Bone Miner. Res., 2008, 23, 803-811.
23. Jolette, J.; Wilker, C.E.; Smith, S.Y.; Doyle, N.; Hardisty, J.F.; Metcalfe, A.J.; Marriott, T.B.; Fox, J.; Wells, D.S. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats. Toxicol. Pathol., 2006, 34, 929-940.
24. Nemeth, E.F. ZT-031, a cyclized analog of parathyroid hormone(1-31) for the potential treatment of osteoporosis. IDrugs, 2008, 11, 827-840.
25. Jolette, J.; Smith, S.Y.; Moreau I.A.; Turner, C.H.; Mayer, J.; Rushton, B.; Morley, P.J. Ostabolin-C: a novel parathyroid hormone analogue uncouples bone turnover in monkeys treated for 1-year. J. Bone Miner. Res., 2005, 20, 9.
26. Martin, T.J.; Moseley, J.M. & Williams, E.D. Parathyroid hormone-related protein: hormone and cytokine. J. Endocrinol., 1997, (Suppl. 154), S23-S37.
27. Miao, D.; He, B.; Jiang, Y.; Kobayashi, T.; Soroceanu, M.A.; Zhao, J.; Su, H.; Tong, X.; Amizuka, N.; Gupta, A.; Genant, H.K.; Kronenberg, H.M.; Goltzman, D.; Karaplis, A.C. Osteoblastderived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J. Clin. Invest., 2005, 115, 2402-2411.
28. Horwitz, M.J.; Tedesco, M.B.; Garcia-Ocana, A.; Sereika, S.M.; Prebehala, L.; Bisello, A.; Hollis, B.W.; Gundberg, C.M.; Stewart, A.F. Parathyroid hormone-related protein for the treatment of postmenopausal osteoporosis: defining the maximal tolerable dose. J. Clin. Endocrinol. Metab., 95, 1279-1287.
29. Brown, E.M. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev., 1991, 71, 371-411.
30. Hosokawa, Y.; Pollak, M.R.; Brown, E.M.; Arnold, A. Mutational analysis of the extracellular Ca(2+)-sensing receptor gene in human parathyroid tumors. J. Clin. Endocrinol. Metab., 1995, 80, 3107-3110.
31. Colloton, M.; Shatzen, E.; Miller, G.; Stehman-Breen, C.; Wada, M.; Lacey, D.; Martin, D. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int., 2005, 67, 467-476.
32. Pearce, S.H.; Williamson, C.; Kifor, O.; Bai, M.; Coulthard, M.G.; Davies, M.; Lewis-Barned, N.; McCredie, D.; Powell, H.; Kendall-Taylor, P.; Brown, E.M.; Thakker, R.V. A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calciumsensing receptor. N. Engl. J. Med., 1996, 335, 1115-1122.
33. Rodriguez, M.; Nemeth, E.; Martin, D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am. J. Physiol. Renal Physiol., 2005, 288, F253-F264.
34. Nemeth, E.F.; Heaton, W.H.; Miller, M.; Fox, J.; Balandrin, M.F.; Van Wagenen, B.C.; Colloton, M.; Karbon, W.; Scherrer, J.; Shatzen, E.; Rishton, G.; Scully, S.; Qi, M.; Harris, R.; Lacey, D.; Martin, D. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther., 2004, 308, 627-635.
35. Nemeth, E.F. The search for calcium receptor antagonists (calcilytics). J. Mol. Endocrinol., 2002, 29, 15-21.
36. Nemeth, E.F.; Delmar, E.G.; Heaton, W.L.; Miller, M.A.; Lambert, L.D.; Conklin, R.L.; Gowen, M.; Gleason, J.G.; Bhatnagar, P.K.; Fox, J. Calcilytic compounds: potent and selective Ca2+ receptor antagonists that stimulate secretion of parathyroid hormone. J. Pharmacol. Exp. Ther., 2001, 299, 323-331.
37. Marquis, R.W.; Lago, A.M.; Callahan, J.F.; Trout, R.E.; Gowen, M.; DelMar, E.G.; Van Wagenen, B.C.; Logan, S.; Shimizu, S.; Fox, J.; Nemeth, E.F.; Yang, Z.; Roethke, T.; Smith, B.R.; Ward, K.W.; Lee, J.; Keenan, R.M.; Bhatnagar, P. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem., 2009, 52, 3982-3993.
38. Marquis, R.W.; Lago, A.M.; Callahan, J.F.; Rahman, A.; Dong, X.; Stroup, G.B.; Hoffman, S.; Gowen, M.; DelMar, E.G.; Van Wagenen, B.C.; Logan, S.; Shimizu, S.; Fox, J.; Nemeth, E.F.; Roethke, T.; Smith, B.R.; Ward, K.W.; Bhatnagar, P. Antagonists of the calcium receptor. 2. Amino alcohol-based parathyroid hormone secretagogues. J. Med. Chem., 2009, 52, 6599-6605.
39. Miedlich, S.U.; Gama, L.; Seuwen, K.; Wolf, R.M.; Breitwieser, G.E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem., 2004, 279, 7254-7263.
40. Petrel, C.; Kessler, A.; Maslah, F.; Dauban, P.; Dodd, R.H.; Rognan, D.; Ruat, M. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca2+-sensing receptor. Journal of Biological Chemistry, 2003, 278, 49487-49494.
41. Kessler, A.; Faure, H.; Petrel, C.; Rognan, D.; Cesario, M.; Ruat, M.; Dauban, P. & Dodd, R. H. N-1-benzoyl-N-2-[1-(1-naphthyl)ethyl]-trans-1,2-diaminocyclohexanes: Development of 4-chlorophenylcarboxamide (Calhex 231) as a new calcium sensing receptor ligand demonstrating potent calcilytic activity. J. Med. Chem., 2006, 49, 5119-5128.
42. Gowen, M.; Stroup, G.B.; Dodds, R.A.; James, I.E.; Votta, B.J.; Smith, B.R.; Bhatnagar, P.K.; Lago, A.M.; Callahan, J.F.; DelMar, E.G.; Miller, M.A.; Nemeth, E.F.; Fox, J. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest., 2000, 105, 1595-1604.
43. Fitzpatrick, L.A.B.E.; Kumar, S.; Matheny, C.; Yi, B.; McLaughlin, M.; Phillips, J.; Skordos, L.; Ethgen, D. Ronacaleret, a Novel Calcium-Sensing Receptor Antagonist, Demonstrates Potential as an Oral Bone-Forming Therapy in Healthy Postmenopausal Women. J. Bone Miner. Metab., 2008, 23, S50.
44. Shcherbakova, I.; Balandrin, M.F.; Fox, J.; Ghatak, A.; Heaton, W.L.; Conklin, R.L. 3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis. Bioorg. Med. Chem. Lett., 2005, 15, 1557-1560.
45. Widler, L.; Altmann, E.; Beerli, R.; Breitenstein, W.; Bouhelal, R.; Buhl, T.; Gamse, R.; Gerspacher, M.; Halleux, C.; John, M.R.; Lehmann, H.; Kalb, O.; Kneissel, M.; Missbach, M.; Muller, I.R.; Reidemeister, S.; Renaud, J.; Taillardat, A.; Tommasi, R.; Weiler, S.; Wolf, R.M.; Seuwen, K. 1-Alkyl-4-phenyl-6-alkoxy-1Hquinazolin-2-ones: a novel series of potent calcium-sensing receptor antagonists. J. Med. Chem., 2010, 53, 2250-2263.
46. Bilezikian, J.P.; Matsumoto, T.; Bellido, T.; Khosla, S.; Martin, J.; Recker, R.R.; Heaney, R.; Seeman, E.; Papapoulos, S.; Goldring, S.R. Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR workshop. J. Bone Miner. Res., 2009, 24, 373-385.
47. Widler, L.G.R.; Seuwen, K.; Buhl, T.; Beerli, R.; Breitenstein, W.; Gyaw, S.; Reynolds, C.; Bruin, G.; Belleli, R.; Klickstein, L.; John, M.R. A Novel Calcium-sensing Receptor Antagonist Leads to Dose-Dependent Transient Release of Parathyroid Hormone after Oral Administration to Healthy Volunteers-an Initial Proof-of-Concept for a Potential New Class of Anabolic Osteoporosis Therapeutics. J Bone Miner Res, 2008, 23, S49.
48. Balan, G.; Bauman, J.; Bhattacharya, S.; Castrodad, M.; Healy, D.R.; Herr, M.; Humphries, P.; Jennings, S.; Kalgutkar, A.S.; Kapinos, B.; Khot, V.; Lazarra, K.; Li, M.; Li, Y.; Neagu, C.; Oliver, R.; Piotrowski, D.W.; Price, D.; Qi, H.; Simmons, H.A.; Southers, J.; Wei, L.; Zhang, Y.; Paralkar, V.M. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg. Med. Chem. Lett., 2009, 19, 3328-3332.
49. Rittmaster, R.S.; Bolognese, M.; Ettinger, M.P.; Hanley, D.A.; Hodsman, A.B.; Kendler, D.L.; Rosen, C.J. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J. Clin. Endocrinol. Metab., 2000, 85, 2129-2134.
50. Greenspan, S.L.; Bone, H.G.; Ettinger, M.P.; Hanley, D.A.; Lindsay, R.; Zanchetta, J.R.; Blosch, C.M.; Mathisen, A.L.; Morris, S.A.; Marriott, T.B. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann. Intern. Med., 2007, 146, 326-339.
51. Gasser, J.A. Potential and limitations of bone anabolic therapy with parathyroid hormone. Eur. Cell. Mater., 2003, 5(Suppl. 2), 34-36.
52. Leder, B.Z.; Neer, R.M.; Wyland, J.J.; Lee, H.W.; Burnett-Bowie, S.M.; Finkelstein, J.S. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis. J. Clin. Endocrinol. Metab., 2009, 94, 2915-2921.
53. Kurland, E.S.; Heller, S.L.; Diamond, B.; McMahon, D.J.; Cosman, F.; Bilezikian, J. P. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos. Int., 2004, 15, 992-997.
54. Black, D.M.; Greenspan, S.L.; Ensrud, K.E.; Palermo, L.; McGowan, J.A.; Lang, T. F.; Garnero, P.; Bouxsein, M.L.; Bilezikian, J.P.; Rosen, C.J. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med., 2003, 349, 1207-1215.
55. Keaveny, T.M.; Hoffmann, P.F.; Singh, M.; Palermo, L.; Bilezikian, J.P.; Greenspan, S.L.; Black, D.M. Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J. Bone Miner. Res., 2008, 23, 1974-1982.
56. Abukawa, H.; Mano, H.; Arakawa, T.; Hakeda, Y.; Kimura, H.; Kumegawa, M. Tissue specific expression and differential regulation by 1 alpha,25-dihydroxyvitamin D-3 of the calciumsensing receptor (CaSR) gene in rat kidney, intestine, and calvaria. Cytotechnology, 2001, 35, 81-86.
57. Riccardi, D.; Finney, B.A.; Wilkinson, W.J.; Kemp, P.J. Novel regulatory aspects of the extracellular Ca2+-sensing receptor, CaR. Pflugers Arch., 2009, 458, 1007-1022.
58. Huang, Y.; Breitwieser, G.E. Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis. J. Biol. Chem., 2007, 282, 9517-9525.
59. Letz, S.; Rus, R.; Haag, C.; Dorr, H.G.; Schnabel, D.; Mohlig, M.; Schulze, E.; Frank-Raue, K.; Raue, F.; Mayr, B.; Schofl, C. Novel Activating Mutations of the Calcium-Sensing Receptor: The Calcilytic NPS-2143 Mitigates Excessive Signal Transduction of Mutant Receptors. J. Clin. Endocrinol. Metab., 2010, 95, E229-E233.
60. Riccardi, D.; Hall, A.E.; Chattopadhyay, N.; Xu, J.Z.; Brown, E.M.; Hebert, S.C. Localization of the extracellular Ca2+ polyvalent cation-sensing protein in rat kidney. Am. J. Physiol. Renal Physiol., 1998, 43, F611-F622.
61. Dvorak, M.M.; Siddiqua, A.; Ward, D.T.; Carter, D.H.; Dallas, S.L.; Nemeth, E.F.; Riccardi, D. Physiological changes in extracellular calcium concentration directly control osteoblast function in the absence of calciotropic hormones. Proc. Natl. Acad. Sci. USA, 2004, 101, 5140-5145.
62. Riccardi, D.; Brown, E.M. Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal Physiol., 2010, 298, F485-F499.
63. Mentaverri, R.; Yano, S.; Chattopadhyay, N.; Petit, L.; Kifor, O.; Kamel, S.; Terwilliger, E.F.; Brazier, M.; Brown, E.M. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J., 2006, 20, 2562-2564.
64. Allbright, F., Ellsworth, R. Studies on the physiology of the parathyroid glands: I. Calcium and Phosphorus Studies on a Case of Idiopathic Hypoparathyroidism. J. Clin. Invest., 1929, 7, 183-201.